WeVote
Log In

Bill

Bill

S 3102

Amendment S.3102

194th Legislature (2025-2026) Introduced by Patrick O'Connor and 1 co-sponsor

Establish uniform, evidence-based coverage for biomarker testing across all major Massachusetts health plans to ensure diagnosis, treatment, and monitoring are routinely covered wi

0
WeVote Research Nonpartisan
Bill Summary · S 3102

Summary of Bill S.3102 (Amendment to Senate Ways and Means Amendment to FY2027 Appropriations)

This memo provides an accessible overview of the proposed amendment package attached to Senate Bill No. 4 (FY2027 Commonwealth appropriations), as amended by S.3102. The core thrust is to require broad, uniform coverage for biomarker testing across multiple Commonwealth health programs and insurance regimes, with detailed definitions and implementation requirements.

Purpose and intent

  • To establish comprehensive coverage standards for biomarker testing across several Massachusetts General Laws chapters (32A, 118E, 175, 176A, 176B, 176G, and 176G).
  • The aim is to ensure that biomarker testing used to diagnose, treat, manage, or monitor diseases or conditions is covered when supported by medical and scientific evidence, while minimizing disruption to care.

Key provisions and changes

The amendment creates uniform definitions and coverage requirements for biomarker testing and related testing technologies. It appears in six main sections, each applying to a different payer or program:

  • Definitions (shared across sections)

    • Biomarker: An objectively measured characteristic indicating biological status, including gene mutations and protein expression.
    • Biomarker testing: Analysis of tissue, blood, or other specimens for biomarkers (including single analyte tests, multi-panel tests, protein expression, whole exome/genome/transcriptome sequencing).
    • Consensus statements: Independent expert panels with transparent methodology and conflict-of-interest policy.
    • Nationally recognized clinical practice guidelines: Evidence-based guidelines from independent organizations.

  • Coverage for state employee group health programs

    • Applies to active/retired Commonwealth employees insured through the Group Insurance Commission.
    • Requires biomarker testing to be covered under criteria listed in subsection (c).

  • Coverage for Medicaid managed care/related programs

    • Division and contracted insurers/plan sponsors under Medicaid managed care and primary care clinician plans must cover biomarker testing according to criteria in subsection (c).

  • Coverage for hospital service plans and related group policies

    • Applies to hospital service plans and group blanket accident and sickness policies.
    • Requires biomarker testing coverage for Commonwealth residents and employees.

  • Coverage for commercial/individually issued plans

    • Applies to hospital service plan contracts and other group/individual medical service contracts (as delivered within the Commonwealth).
    • Requires biomarker testing coverage consistent with subsection (c).

  • Coverage for health maintenance organizations and other private plans

    • Applies to individual or group health maintenance contracts within or outside the Commonwealth.
    • Requires biomarker testing coverage consistent with subsection (c).

  • Common features across all sections

    • Covered uses: Diagnosis, treatment, appropriate management, or ongoing monitoring of a disease/condition.
    • Evidence basis: Coverage aligns with FDA-labeled indications, FDA-approved drug indications, drug label warnings/precautions, CMS national or MAC local coverage determinations, and nationally recognized guidelines/consensus statements.
    • Care continuity: Coverage must limit disruptions in care (e.g., avoid unnecessary repeat biopsies or sampling).
    • Prior authorization: If prior authorization is required, decisions must be issued within 72 hours; urgent cases with significant risk may be decided within 24 hours. If no decision is issued within the required timeframe, the request is deemed granted.
    • Appeals: Clear processes for exceptions to coverage policies or adverse utilization determinations must be accessible on the insurer’s website.

  • Accessibility and exceptions

    • Patients and prescribing practitioners must have access to straightforward processes to request exceptions or challenge adverse determinations.

Who is affected

  • State employees and retirees covered by the Group Insurance Commission.
  • Medicaid managed care beneficiaries and related plans under Commonwealth programs.
  • Subscribers and enrollees in hospital service plans, group accident/sickness policies, and other comprehensive health coverage both within and outside the Commonwealth.
  • Health insurers, health plans, HMO entities, behavioral health management firms, and third-party administrators contracting with Medicaid or private plans.

Procedural and timeline aspects

  • The language indicates insertion of a new Section 17R into Chapter 32A and corresponding sections into Chapters 118E, 175, 176A, 176B, and 176G of the General Laws.
  • The amendment follows the structure of an appropriation bill (House FY2027 maintenance and related items) but focuses on establishing mandatory coverage standards rather than creating new funding lines.
  • Key timing milestones revolve around prior authorization processing timelines (72 hours to decide, 24 hours in urgent cases) and a deemed-granted rule if no timely decision is issued.

Practical impact and considerations

  • Standardized coverage for biomarker testing could increase access to precision medicine approaches for a broad set of enrollees.
  • Insurers would need to align policies with the specified evidence-based criteria, potentially affecting cost, utilization, and prior authorization workflows.
  • The emphasis on minimizing care disruptions could reduce patients’ need for repeat tests or biopsies.
  • Administrative requirements include publicly accessible exception processes and timely determinations to ensure predictable coverage decisions.

If you’d like, I can provide a side-by-side comparison of sections by payer type, or a brief impact assessment focused on cost, access, and implementation challenges.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.